Basil Darras, MD
Neurology with Special Qualifications in Child Neurology · Boston, MANPI 1538191309
Payments from drug & device makers
Across 509 payments — averaging $16,585 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$4.7M
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$938K
- Sarepta Therapeutics, Inc.$927K
- Hoffmann-la Roche Limited$856K
- Genentech, Inc.$489K
- Novartis$285K
- plus $281K from 13 others
Across 73 payments — averaging $710.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$40K
- Novartis$5K
- Novartis Pharma AG$3K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$3K
- Biogen$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 40 | $4,665,485 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 158 | $938,121 |
| Sarepta Therapeutics, Inc. | 92 | $926,963 |
| Hoffmann-la Roche Limited | 47 | $856,199 |
| Genentech, Inc. | 10 | $488,547 |
| Novartis | 16 | $285,243 |
| PTC Therapeutics, Inc. | 47 | $109,909 |
| F. Hoffmann-la Roche AG | 58 | $78,563 |
| Vertex | 6 | $30,166 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27,000 |
| Genentech USA, Inc. | 15 | $17,489 |
| Argenx US, Inc. | 7 | $6,238 |
| Sanofi | 1 | $3,276 |
| Amicus Therapeutics, Inc. | 4 | $3,000 |
| Merck | 1 | $2,060 |
| Ipsen Bioscience Inc. | 2 | $1,249 |
| Roche Products Limited | 2 | $1,245 |
| Pfizer | 1 | $825 |
| Travere Therapeutics, Inc. | 1 | $1 |
How this compares
$8,441,577 in reported general payments places this provider in the 95th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
See all neurology with special qualifications in child neurology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology with special qualifications in child neurology in Boston
- Mustafa SahinBoston$8M
- Elizabeth ThieleBoston$1.4M
- David LiebermanBoston$935K
- Alexander RotenbergBoston$870K
- Kiran MaskiBoston$696K
- Leslie BensonBoston$467K
- Jurriaan PetersBoston$379K
- Tobias LoddenkemperBoston$365K
- Ann NeumeyerBoston$312K
- Phillip PearlBoston$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.